Pierre Bay1, Guillaume Lebreton2, Alexis Mathian3,4, Pierre Demondion2, Cyrielle Desnos1, Juliette Chommeloux1, Guillaume Hékimian1, Nicolas Bréchot1, Ania Nieszkowska1, Matthieu Schmidt1,5, Fleur Cohen-Aubart3,4, Pascal Leprince2, Charles-Edouard Luyt1,5, Zahir Amoura3,4, Alain Combes1,5, Marc Pineton de Chambrun6,7,8,9. 1. Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France. 2. Service de Chirurgie Cardiothoracique, Hôpital La Pitié-Salpêtrière, Institut de Cardiologie, Sorbonne Université, APHP, Paris, France. 3. Service de Médecine Interne 2, Institut E3M, Sorbonne Université, Hôpital La Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France. 4. Centre de Référence National Lupus Systémique, Syndrome Des Anticorps Anti-Phospholipides Et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France. 5. Institut de Cardiométabolisme Et Nutrition (ICAN), Sorbonne Université, INSERM, UMRS_1166-ICAN, Paris, France. 6. Service de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France. marc.dechambrun@gmail.com. 7. Service de Médecine Interne 2, Institut E3M, Sorbonne Université, Hôpital La Pitié-Salpêtrière, 47-83, Boulevard de L'Hôpital, 75651, Paris Cedex 13, France. marc.dechambrun@gmail.com. 8. Centre de Référence National Lupus Systémique, Syndrome Des Anticorps Anti-Phospholipides Et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France. marc.dechambrun@gmail.com. 9. Institut de Cardiométabolisme Et Nutrition (ICAN), Sorbonne Université, INSERM, UMRS_1166-ICAN, Paris, France. marc.dechambrun@gmail.com.
Abstract
BACKGROUND: Systemic rheumatic diseases (SRDs) are a group of inflammatory disorders that can require intensive care unit (ICU) admission because of multiorgan involvement with end-organ failure(s). Critically ill SRD patients requiring extracorporeal membrane oxygenation (ECMO) were studied to gain insight into their characteristics and outcomes. METHODS: This French monocenter, retrospective study included all SRD patients requiring venovenous (VV)- or venoarterial (VA)-ECMO admitted to a 26-bed ECMO-dedicated ICU from January 2006 to February 2020. The primary endpoint was in-hospital mortality. RESULTS: Ninety patients (male/female ratio: 0.5; mean age at admission: 41.6 ± 15.2 years) admitted to the ICU received VA/VV-ECMO, respectively, for an SRD-related flare (n = 69, n = 38/31) or infection (n = 21, n = 10/11). SRD was diagnosed in-ICU for 31 (34.4%) patients. In-ICU and in-hospital mortality rates were 48.9 and 51.1%, respectively. Nine patients were bridged to cardiac (n = 5) or lung transplantation (n = 4), or left ventricular assist device (n = 2). The Cox multivariable model retained the following independent predictors of in-hospital mortality: in-ICU SRD diagnosis, day-0 Simplified Acute Physiology Score (SAPS) II score ≥ 70 and arterial lactate ≥ 7.5 mmol/L for VA-ECMO-treated patients; diagnosis other than vasculitis, day-0 SAPS II score ≥ 70, ventilator-associated pneumonia and arterial lactate ≥ 7.5 mmol/L for VV-ECMO-treated patients. CONCLUSIONS: ECMO support is a relevant rescue technique for critically ill SRD patients, with 49% survival at hospital discharge. Vasculitis was independently associated with favorable outcomes of VV-ECMO-treated patients. Further studies are needed to specify the role of ECMO for SRD patients.
BACKGROUND: Systemic rheumatic diseases (SRDs) are a group of inflammatory disorders that can require intensive care unit (ICU) admission because of multiorgan involvement with end-organ failure(s). Critically illSRDpatients requiring extracorporeal membrane oxygenation (ECMO) were studied to gain insight into their characteristics and outcomes. METHODS: This French monocenter, retrospective study included all SRDpatients requiring venovenous (VV)- or venoarterial (VA)-ECMO admitted to a 26-bed ECMO-dedicated ICU from January 2006 to February 2020. The primary endpoint was in-hospital mortality. RESULTS: Ninety patients (male/female ratio: 0.5; mean age at admission: 41.6 ± 15.2 years) admitted to the ICU received VA/VV-ECMO, respectively, for an SRD-related flare (n = 69, n = 38/31) or infection (n = 21, n = 10/11). SRD was diagnosed in-ICU for 31 (34.4%) patients. In-ICU and in-hospital mortality rates were 48.9 and 51.1%, respectively. Nine patients were bridged to cardiac (n = 5) or lung transplantation (n = 4), or left ventricular assist device (n = 2). The Cox multivariable model retained the following independent predictors of in-hospital mortality: in-ICU SRD diagnosis, day-0 Simplified Acute Physiology Score (SAPS) II score ≥ 70 and arterial lactate ≥ 7.5 mmol/L for VA-ECMO-treated patients; diagnosis other than vasculitis, day-0 SAPS II score ≥ 70, ventilator-associated pneumonia and arterial lactate ≥ 7.5 mmol/L for VV-ECMO-treated patients. CONCLUSIONS: ECMO support is a relevant rescue technique for critically illSRDpatients, with 49% survival at hospital discharge. Vasculitis was independently associated with favorable outcomes of VV-ECMO-treated patients. Further studies are needed to specify the role of ECMO for SRDpatients.
Authors: Alain Combes; Daniel Brodie; Robert Bartlett; Laurent Brochard; Roy Brower; Steve Conrad; Daniel De Backer; Eddy Fan; Niall Ferguson; James Fortenberry; John Fraser; Luciano Gattinoni; William Lynch; Graeme MacLaren; Alain Mercat; Thomas Mueller; Mark Ogino; Giles Peek; Vince Pellegrino; Antonio Pesenti; Marco Ranieri; Arthur Slutsky; Alain Vuylsteke Journal: Am J Respir Crit Care Med Date: 2014-09-01 Impact factor: 21.405
Authors: Alain Combes; David Hajage; Gilles Capellier; Alexandre Demoule; Sylvain Lavoué; Christophe Guervilly; Daniel Da Silva; Lara Zafrani; Patrice Tirot; Benoit Veber; Eric Maury; Bruno Levy; Yves Cohen; Christian Richard; Pierre Kalfon; Lila Bouadma; Hossein Mehdaoui; Gaëtan Beduneau; Guillaume Lebreton; Laurent Brochard; Niall D Ferguson; Eddy Fan; Arthur S Slutsky; Daniel Brodie; Alain Mercat Journal: N Engl J Med Date: 2018-05-24 Impact factor: 91.245
Authors: B Godeau; A Boudjadja; J F Dhainaut; B Schlemmer; C Chastang; F Brunet; J R Le Gall Journal: Ann Rheum Dis Date: 1992-05 Impact factor: 19.103
Authors: Romaric Larcher; Marc Pineton de Chambrun; Fanny Garnier; Emma Rubenstein; Julie Carr; Jonathan Charbit; Kevin Chalard; Marc Mourad; Matthieu Amalric; Laura Platon; Vincent Brunot; Zahir Amoura; Samir Jaber; Boris Jung; Charles-Edouard Luyt; Kada Klouche Journal: Chest Date: 2020-04-11 Impact factor: 9.410
Authors: Darryl Abrams; A Reshad Garan; Akram Abdelbary; Matthew Bacchetta; Robert H Bartlett; James Beck; Jan Belohlavek; Yih-Sharng Chen; Eddy Fan; Niall D Ferguson; Jo-Anne Fowles; John Fraser; Michelle Gong; Ibrahim F Hassan; Carol Hodgson; Xiaotong Hou; Katarzyna Hryniewicz; Shingo Ichiba; William A Jakobleff; Roberto Lorusso; Graeme MacLaren; Shay McGuinness; Thomas Mueller; Pauline K Park; Giles Peek; Vin Pellegrino; Susanna Price; Erika B Rosenzweig; Tetsuya Sakamoto; Leonardo Salazar; Matthieu Schmidt; Arthur S Slutsky; Christian Spaulding; Hiroo Takayama; Koji Takeda; Alain Vuylsteke; Alain Combes; Daniel Brodie Journal: Intensive Care Med Date: 2018-02-15 Impact factor: 17.440